139194-79-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-nitrobenzyl alcohol is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of drug molecules, contributing to the development of new medications and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-5-nitrobenzyl alcohol is employed as a precursor in the production of pesticides and other agrochemicals. Its reactivity and functional groups enable the synthesis of effective compounds designed to protect crops and enhance agricultural productivity.
Used in Organic Material Synthesis:
3-Bromo-5-nitrobenzyl alcohol is used as a versatile intermediate for the synthesis of organic materials, including dyes, polymers, and other specialty chemicals. Its structural features facilitate the development of innovative materials with unique properties and applications.
Used in Research and Development:
3-Bromo-5-nitrobenzyl alcohol is also employed in research and development settings, where its reactivity and structural attributes are harnessed to explore new chemical reactions and syntheses. This contributes to the advancement of organic chemistry and the discovery of novel compounds with potential applications across various industries.

Upstream product

• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 111532-78-6 borane dimethyl sulfide complex 
• 121-92-6 3-nitrobenzoic acid 
• 6307-87-5 methyl 3-bromo-5-nitrobenzoate 

Downstream Products

• 318261-49-3 1-bromo-3-(chloromethyl)-5-nitrobenzene 
• 954124-45-9 3-amino-5-bromobenzylic alcohol 
• 318261-53-9 3-bromo-5-aminobenzyl 2-[2-(2-methoxyethoxy)ethoxy]ethyl ether 
• 318261-51-7 3-bromo-5-nitrobenzyl 2-[2-(2-methoxyethoxy)ethoxy]ethyl ether 
• 318262-19-0 3-iodo-5-(2-trimethylsilylethynyl)benzyl 2-[2-(2-methoxyethoxy)ethoxy]ethyl ether 
• 318262-30-5 1-Ethynyl-3-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxymethyl}-5-(3-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxymethyl}-phenylethynyl)-benzene 
• 318262-29-2 [3-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxymethyl}-5-(3-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxymethyl}-phenylethynyl)-phenylethynyl]-trimethyl-silane 
• 318262-32-7 C₆₄H₈₂O₁₆ 
• 318262-31-6 C₆₇H₉₀O₁₆Si 
• 139194-80-2 1-bromo-3-(bromomethyl)-5-nitrobenzene 
• 1202036-22-3 4-(3-bromo-5-nitrobenzyl)-2,6-dimethylmorpholine 
• 1202036-25-6 (3-(1-methyl-1H-pyrazol-4-yl)-5-nitrophenyl)methanol 
• 1273594-29-8 3-amino-5-bromobenzyl acetate 
• 1273594-30-1 3-amino-5-bromobenzyl benzoate 

Relevant academic research and scientific papers

A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove

Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low density lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction promotes elevated plasma LDL cholesterol levels and a predisposition to cardiovascular disease (CVD), it has attracted much interest as a therapeutic target. While anti-PCSK9 monoclonal antibodies have been successful in the treatment of hypercholesteremia by decreasing CVD risk, their high cost and a requirement for injection have prohibited widespread use. The advent of an orally bioavailable small molecule inhibitor of the PCSK9-LDLR interaction is an attractive alternative, however efforts have been tempered as the binding interface is unfavourable for binding by small organic molecules. Despite its challenging nature, we report herein the discovery of compound 3f as a small molecule inhibitor of PCSK9. The kinase inhibitor nilotinib emerged from a computational screen that was applied to identify compounds that may bind to a cryptic groove within PCSK9 and proximal to the LDLR-binding interface. A subsequent in vitro PCSK9-LDLR binding assay established that nilotinib was a bona fide but modest inhibitor of the interaction (IC50 = 9.8 μM). Through multiple rounds of medicinal chemistry, 3f emerged as a lead-like molecule by demonstrating disruption of the PCSK9-LDLR interaction at nanomolar levels in vitro (IC50 = 537 nM) with no inhibitory activity (IC50 > 10 μM) against a small panel of kinases. Compound 3f restored LDL uptake by liver cells at sub-micromolar levels and demonstrated excellent bioavailability when delivered subcutaneously in mice. Most significantly, compound 3f lowered total cholesterol levels in the plasma of wild-type mice, thereby providing proof-of-concept that the notion of a small molecule inhibitor against PCSK9 is therapeutically viable.

Pyrimidine compounds and pharmaceutical composition for preventing or treating cancers comprising the same

The present invention relates to a pyrimidine compound having excellent FLT3 inhibitory activity, and a pharmaceutical composition for preventing or treating a cancer, including the same. The pyrimidine compound is represented by chemical formula 14, wherein the pyrimidine compound is selected from a stereoisomer, a tautomer, a solvate, and a pharmaceutically acceptable salt thereof. In the chemical formula 14, E^a is hydrogen, hydroxy or C_(1-4) alkoxy, and E^b is hydrogen, halogen, C_(1-4) alkyl or C_(1-4) fluoroalkyl.COPYRIGHT KIPO 2019

PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.

HETEROCYCLIC INHIBITORS OF PCSK9

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): (I) wherein A, D and Q are described herein.

Switchable 3D networks by light controlled π-stacking of azobenzene macrocycles

Azobenzene macrocycles were designed for switchable π-stacking interaction. After efficient preparation and characterization of azobenzene macrocycles containing electron rich as well as electron poor elements a dimeric analogue was synthesized, which formed reversibly 3D-networks. Gel formation was observed with aromatic solvents representing the first example of this type based on switchable azobenzene macrocycles. The Royal Society of Chemistry.

Synthesis and isomerization studies of cyclotrisazobiphenyl

We report an efficient synthesis of cyclotris[(E)-3′-(biphenyl-3- yldiazenyl)] compounds (CTBs). An unsubstituted CTB molecule is accessible in four steps in 10% yield overall, whereas a hexa(methoxymethyl ether) CTB analogue was prepared in nine steps (26% yield). The final macrocyclization step was accomplished in up to 80% yield by using a metal-template effect. Furthermore, the photochromic properties were investigated, and all four isomers were detected and characterized by NMR spectroscopy. A strong influence from the solvent and the irradiation wavelength on the switching process was observed. Irradiation in pyridine yielded the highest amount of the all-Z isomer in the photostationary state. For a full conversion to the all-E isomer, the reaction has to be heated to 45°C. The isomerization to the all-E isomer is slow at room temperature, with a half-life time of the all-Z isomer of more than nine days in dimethyl sulfoxide (DMSO). Conditions were established to access each possible isomer as the major component in the photostationary state.

2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES

The invention provides novel compounds that are inhibitors of PDKI. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or composition.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

SULFONYL-SUBSTITUTED ARYL COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS

Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders

Aryl sulfonamide and sulfonyl compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.